Centessa Pharmaceuticals plc (CNTA)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| License and other revenue | - | 15 | ||
| Research and development | 42.741 | 33.443 | ||
| General and administrative | 11.912 | 12.334 | ||
| Loss from operations | -54.653 | -30.777 | ||
| Interest and investment income | 4.38 | 7.89 | ||
| Interest expense | 2.884 | 2.877 | ||
| Other non-operating income (expense), net | 3.592 | 1.026 | ||
| Loss before income taxes | -49.565 | -24.738 | ||
| Income tax expense | 0.778 | 1.397 | ||
| Net loss | -50.343 | -26.135 | ||
| Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax | -0.005 | -2.781 | ||
| Foreign currency translation adjustment | -0.479 | 0.643 | ||
| Other comprehensive (loss) income | -0.484 | -2.138 | ||
| Total comprehensive loss | -50.827 | -28.273 | ||
| Net loss per ordinary share - basic (in dollars per share) | -0.38 | -0.2 | ||
| Net loss per ordinary share - diluted (in dollars per share) | -0.38 | -0.2 | ||
| Weighted average ordinary shares outstanding - basic (in shares) | 133,677,405 | 133,033,541 | ||
| Weighted average ordinary shares outstanding - diluted (in shares) | 133,677,405 | 133,033,541 | ||